Furthermore, the prevalence calculated for PSL among cancer patients and prostate cancer patients alone are likely understated because they are based on the total number of FDG and PSMA PET/CT studies for suspected and confirmed malignancies, and we could not distinguish between those with definite cancers and in particular, those with disseminated disease. This evidence concerns the gene FOLH1 and prostate cancer.